medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Número 3

<< Anterior Siguiente >>

Ann Hepatol 2018; 17 (3)


Thrombosis of the Portal Venous System in Cirrhotic vs. Non-Cirrhotic Patients

Cruz-Ramón V, Chinchilla-López P, Ramírez-Pérez O, Aguilar-Olivos NE, Alva-López LF, Fajardo-Ordoñez E, Ponciano-Rodríguez G, Northup PG, Intagliata N, Caldwell SH, Qi X, Méndez-Sánchez N

Idioma: Ingles.
Referencias bibliográficas: 26
Paginas: 476-481
Archivo PDF: 175.05 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Manzano-Robleda MC, Barranco-Fragoso B, Uribe M, Méndez- Sánchez N. Portal vein thrombosis: what is new? Ann Hepatol 2015; 1: 20-7.

  2. Von Köckritz L, De Gottardi A, Trebicka J, Praktiknjo M. Portal vein thrombosis in patients with cirrhosis. Gastroenterology Report 2017; 2: 148-56.

  3. Tripodi A, Primignani M, Chantarangku V, Dell’Era A, Clerici M, de Franchis R, Colombo M, et al. An imbalance of pro- vs. anti-n coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009; 6: 2105-11.

  4. Northup PG, Sundaram V, Fallon MB, Reddy KR, Balogun RA, Sanyal AJ, Anstee QM, et al. Hypercoagulation and thrombophilia in liver disease. J Thromb Haemost 2008; 1: 2-9.

  5. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, Mannuccio Mannucci P. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 3: 553-8.

  6. Muciño-Bermejo J, Carrillo-Esper R, Méndez-Sánchez N, Uribe M. Thrombosis and hemorrhage in the critically ill patients with cirrhosis: five years retrospective prevalence study. Ann Hepatol 2015; 1: 93-8

  7. Ogren M, Bergqvist D, Björck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol 2006; 13: 2115-9.

  8. Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 2010; 3: 366-74.

  9. Senzolo M, Burra P, Cholongitas E, Burroughs A. New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol 2006; 48: 7725-36.

  10. Yerdel MA, Gunson B, Mirza D, Karayalçin K, Olliff S, Buckels J, Mayer D, et al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation 2000; 9: 1873-81.

  11. Rajani R, Bjornsson E, Bergquis A, Danielsson A, Gustavsson A, Grip O, Melin T. The epidemiology and clinical features of portal vein thrombosis: a multicentre study. Aliment Pharmacol Ther 2010; 9: 1154-62.

  12. Parikh S, Shah R, Kapoor P. Portal vein thrombosis. Am J Med 2010; 2: 111-9

  13. Sacerdoti D, Serianni G, Gaiani S, Bolognesi M, Bombonato G, Gatta A. Thrombosis of the portal venous system. J Ultrasound 2007; 1: 12-21.

  14. Loudin M, Ahn J. Portal Vein Thrombosis in Cirrhosis. J Clin Gastroenterol 2017; 7: 579-85.

  15. Chawla YK, Bodh V. Portal Vein Thrombosis. J Clin Experimental Hepatol 2015; 1: 22-40.

  16. Pungpapong S, Manzarbeitia C, Ortiz J, Reich DJ, Araya V, Rothstein KD, Muñoz SJ. Cigarette Smoking Is Associated With an Increased Incidence of Vascular Complications After Liver Transplantation. Liv Transplant 2002; 7: 582-7.

  17. Rebours V, Boudaoud L, Vullierme MP, Vidaud D, Condat B, Hentic O, Maire F, et al. Extrahepatic Portal Venous System Thrombosis in Recurrent Acute and Chronic Alcoholic Pancreatitis Is Caused by Local Inflammation and Not Thrombophilia. Am J Gastroenterol 2012; 10: 1579-85.

  18. Dell’Era A, Seijo S. Portal vein thrombosis in cirrhotic and non-cirrhotic patients: from diagnosis to treatment. Expert Opinion on Orphan Drugs 2016; 9: 927-40.

  19. Tublin ME, Dodd GD 3rd, Baron RL. Benign and malignant portal vein thrombosis: differentiation by CT characteristics. Am J Roentgenol 1997; 3: 719-23.

  20. Hoekstra J, Janssen HL. Vascular liver disorders (II): portal vein thrombosis. Neth J Me 2009; 2: 46-53.

  21. Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, Muggeo M, et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 2008; 6: 1394-9.

  22. Targher G, Zoppini G, Moghetti P, Day CP. Disorders of coagulation and hemostasis in abdominal obesity: emerging role of fatty liver. Semin Thromb Hemost 2010; 1: 41-8.

  23. Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 2009; 3: 277-87.

  24. Day CP. From fat to inflammation. Gastroenterology 2006; 130: 207-10.

  25. Alessi MC, Bastelica D, Mavri A, Morange P, Berthet B, Grino M, Juhan-Vague I. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol 2003; 23: 1262-8.

  26. Stine JG, Shah NL, Argo CK, Pelletier SJ, Caldwell SH, Northup PG. Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis. Liver Transpl 2015; 8: 1016-21.




2020     |     www.medigraphic.com